NCT03070392Phase 2Completed

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

Study sponsor: Immunocore Ltd

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2020-10-13Actual
Enrollment · participants378Actual
Source updated2026-10-29Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Efficacy: Overall Survival Description: Overall survival is defined as the time from randomization to date of death due to any cause. Time frame: From randomization to the data cut off date of 13-Oct-2020; median follow-up duration was 14.1 months.. After: Measure: Overall Survival Description: Overall survival is defined as the time from randomization to date of death due to any cause. Time frame: From randomization to the data cut off date of 13-Oct-2020; median follow-up duration was 14.1 months..

Check registry source

· 1 field changed

Recruitment status changed

Before: Active not recruiting. After: Completed.

Check registry source